Filing Details

Accession Number:
0001209191-14-022507
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-03-21 17:43:06
Reporting Period:
2014-03-12
Filing Date:
2014-03-21
Accepted Time:
2014-03-21 17:43:06
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1000694 Novavax Inc NVAX Biological Products, (No Disgnostic Substances) (2836) 222816046
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1461239 Ltd Pharmaceuticals Cadila Cadila Corporate Campus,
Sarkhej- Dholka Road
Bhat, Ahmedabad Gujarat K7 382 210
No No Yes No
1461647 Ltd (Holdings) Overseas Satellite 7 Hill Street, Douglas
Isle Of Man E9 1M1EF
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2014-03-19 1,000,000 $5.17 11,500,000 No 4 S Indirect See footnote
Common Stock Disposition 2014-03-20 1,000,000 $4.99 10,500,000 No 4 S Indirect See footnote
Common Stock Disposition 2014-03-21 1,000,000 $4.69 9,500,000 No 4 S Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.07 to $5.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.87 to $5.19, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.47 to $4.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
  4. These shares are owned directly by Satellite Overseas (Holdings) Limited, which is a wholly owned subsidiary (except for directors' qualifying shares) of Cadila Pharmaceuticals Ltd. Cadila Pharmaceuticals Ltd is an indirect beneficial owner of the reported securities. These shares are held for convenience in the name of "SOHL, Inc., as nominee for Satellite Overseas (Holdings) Limited." SOHL, Inc., has no voting, dispositive or pecuniary interest in any such shares.